Estrella Immunopharma Expands STARLIGHT-1 Trial with New Texas Clinical Site

On Thursday, Estrella Immunopharma Inc. (NASDAQ:ESLA) announced the activation of a second clinical site for its ongoing STARLIGHT-1 Phase I/II clinical trial.

The trial is evaluating EB103, which is a CD19-redirected ARTEMIS® T-cell therapy, in adult patients (aged 18 and older) with relapsed or refractory B-cell non-Hodgkin’s lymphoma (NHL). The new site is now open for patient enrollment, which is Baylor Research Institute d/b/a Baylor Scott & White Research Institute in Dallas, Texas.

A biopharmaceutical facility with technicians working on a manufacturing line of treatments and preventions.

The expansion of the clinical footprint is aimed at accelerating the development of EB103 and increasing patient access to the therapy. Cheng Liu, CEO of Estrella, emphasized that partnering with a nationally recognized institution like Baylor Research Institute is crucial for broadening the trial’s reach and delivering safer and more effective treatments for patients with advanced NHL.

The STARLIGHT-1 Phase I/II trial is an open-label, dose-escalation and multi-center study. Its primary objectives are to assess the safety of EB103 autologous T-cell therapy and to determine the Recommended Phase II Dose (RP2D). The study design includes an initial dose escalation phase, which is then followed by an expansion phase.

Estrella Immunopharma Inc. (NASDAQ:ESLA) is a clinical-stage biopharmaceutical company that develops T-cell therapies for blood cancers and solid tumors in the US.

While we acknowledge the potential of ESLA to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than ESLA and that has 100x upside potential, check out our report about the cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.